NCT03045770

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.

Detailed description

In previous studies, we found that mFOLFOX(a Combination of Oxaliplatin, Fluorouracil), mFOLFIRI(a Combination of Irinotecan, Fluorouracil), FOLFPTX (a Combination of Paclitaxel, Fluorouracil) are active in patients with AGC or EGJA.This study is being done to find out which one has the best efficacy.

Conditions

• Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Interventions

Type	Name	Description
DRUG	Fluorouracil	Fluorouracil was used as first line treatment with AGC.
DRUG	Oxaliplatin	Oxaliplatin was used as first line treatment with AGC.
DRUG	Irinotecan	Irinotecan was used as first line treatment with AGC.
DRUG	Paclitaxel	Paclitaxel was used as first line treatment with AGC.
DRUG	calcium levofolinate	Calcium levofolinate was used as first line treatment with AGC.

Timeline

• Start date: 2017-02-10
• Primary completion: 2019-12-30
• Completion: 2019-12-30
• First posted: 2017-02-07
• Last updated: 2017-02-07

Locations

1 site across 1 country: China